Cancer Genetics to Report Fourth Quarter and Fiscal Year 2014 Financial Results on Thursday, March 12

RUTHERFORD, N.J., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report fourth quarter and fiscal 2014 financial results before the market open on Thursday, March 12, 2015. The company will also hold a live investor conference call and webcast at 8:30am Eastern.

Conference Call & Webcast
Thursday, March 12, 2015 at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
Domestic: 877-407-4018
International: 201-689-8471
Conference ID: 13601913
Webcast: http://public.viavid.com/player/index.php?id=113220
Replays – Available through March 26, 2015
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 13601913

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:

Internet: http://www.cancergenetics.com

Twitter: @Cancer_Genetics

Facebook: www.facebook.com/CancerGenetics

CONTACT: Investor Relations Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 Media Relations Alison Burchett 201-528-2053 media@cgix.comSource:Cancer Genetics, Inc.